A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related

This is a Phase I clinical study aimed to assess the safety, tolerability, and efficacy of SCG101 monotherapy for patients with HBV-HCC.

Trial Details

NCT ID
NCT06617000
Phase
PHASE1
Sponsor
SCG Cell Therapy Pte. Ltd.
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • SCG101
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Changchun, Jilin, China|43.88,125.32278
  • Shenyang, Liaoning, China|41.79222,123.43278

Key Eligibility Criteria

  • Histologically or cytologically confirmed Hepatocellular carcinoma (HCC)
  • Subjects with HCC who have received standard systemic therapies
  • HLA-A \*02
  • BCLC stage B or C

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →